A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis

16298S2213-NCT06022939OpenA Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL AmyloidosisS2213NCT06022939NationalAdultTreatmentIIIUnknown SitesDoucette, KimberleyGeorgetown University Medical Center : Madina Kamilova Galliher; Lombardi Comprehensive Cancer Center : Madina Kamilova GalliherMultiple MyelomaOncology GroupLombardi Comprehensive Cancer Center (LCCC)17888Madina Kamilova GalliherMadina Kamilova Gallihermk2607@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>